Tous Actualités
Suivre
Abonner Resverlogix Corp.

Resverlogix Corp.

Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session

Chicago, November 17 (ots/PRNewswire)

Resverlogix Corp.
("Resverlogix")  announces its top line results of the ASSERT Phase 2
clinical trial which will be highlighted at the prestigious American
Heart Association Scientific Sessions 2010 Late Breaking Clinical
Trial session, by principal investigator Dr. Stephen Nicholls of the
Cleveland Clinic. The top line ASSERT trial data was designed to
answer questions about how to best proceed with future trial designs
for Resverlogix' lead oral small molecule drug RVX-208.
The ASSERT trial data demonstrated that the three key biomarkers
in the reverse cholesterol transport (RCT) process showed dose
dependant and consistent improvement. The trial showed dose dependent
increases in ApoA-l, statistically significant increases in HDL
cholesterol including alpha1 particles or functional HDL, and highly
statistically significant increases in large HDL particles. RCT is a
pathway by which accumulated cholesterol is transported from the
arterial wall to the liver for excretion, thus reducing and/or
preventing atherosclerosis.
In the high dose, ApoA-I achieved a 5.6% increase with a
statistical value of p=0.06. The overall ApoA-I biomarker showed a
dose trending statistical significance of p=0.035. Data presented
also showed that the ApoA-I and other HDL particles continued to be
increasing at the end of the 12 week study. Both the 8.3% HDL
cholesterol increase and the 21.1% large particle HDL increase were
highly statistically significant, p<0.01 and p<0.001 respectively.
These pronounced HDL related increases via ApoA-I production are
important as they take place later in the RCT chain of events and
strongly indicate plaque regression potential.
"These are very encouraging early findings which suggest the drug
(RVX-208) is working in the established patient population that it
was designed for, being patients with advanced coronary disease,"
said Dr. Stephen Nicholls, MBBS, PhD, Medical Director of
Intravascular Ultrasound and Angiography Core Laboratories at
Cleveland Clinic and Clinical Director of the Cleveland Clinic Center
for Cardiovascular Diagnostics and Prevention.
Donald McCaffrey, President and Chief Executive Officer of
Resverlogix commented, "The study largely replicates findings
previously seen in our earlier 28 day trial, more importantly these
findings are now being shown in patients with coronary artery disease
on optimal standard of care. The positive changes seen in this trial
represent advancement over the current best standard of care
available in the USA. We are now well positioned to advance RVX-208
to the next clinical trial having witnessed the substantial and
consistent elevation of HDL by ApoA-I production; which strongly
indicates that RVX-208 should remove unwanted plaque from the
arterial wall which is our main goal."
Resverlogix Senior Vice President of Medical Affairs Dr. Jan
Johansson stated, "In patients who received the newer class of
statins and had baseline HDL below 45mg/dL, an important high-risk
subpopulation, the middle dose of 200 mg saw the most pronounced
increases of 12% in ApoA-I (p<0.002), 21% in HDL cholesterol
(p<0.015) and 32% in large particle HDL (p<0.018). We are delighted
by these results and now have a much better understanding of what
doses to use and what patient population to target moving forward in
our ASSURE Phase 2b trial."
An additional presentation at the AHA meeting was given by Dr.
Norman Wong, Chief Scientific Officer of Resverlogix, containing new
data detailing the effects of RVX-208 in vivo. The presentation was
titled "RVX-208: An Orally Administrated Small Molecule Reduces
Atherosclerosis in ApoE Null Mouse and Raises ApoA-I/HDL in Humans".
In the ApoE null mice model of atherosclerosis, the oral
administration of RVX-208 reduced aortic plaques in two separate
models. The presented model showed plaque reductions of up to 41%.
Resverlogix to Host Webcast on ASSERT Phase 2 Trial Results -
change in time Resverlogix Corp. will host a live teleconference and
webcast today at 2:15 pm Central/1:15 pm Mountain time. The purpose
of the teleconference is to discuss the top line results of the
Company's Phase 2 clinical trial (ASSERT) for RVX-208. The dial-in
numbers for this event are toll free 1-800-319-4610 and international
1-604-638-5340. A link for this webcast will be posted onto the
homepage of Resverlogix's website and can be accessed from the
following address
http://services.choruscall.com/links/resverlogix101117.html.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet medical needs. The NexVas(TM) PR
program is the Company's primary focus which is to develop novel
small molecules that enhance ApoA-l. These vital therapies address
the burden of atherosclerosis and other important diseases such as
Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral
Artery Disease and other vascular disorders. Resverlogix Corp.'s
common shares trade on the Toronto Stock Exchange . For further
information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements
as defined under applicable Canadian securities legislation,
including our statements with respect to research, development and
commercialization of novel therapeutics that reduce the risk of
cardiovascular disease including atherosclerosis, diabetes,
Alzheimer's disease, Peripheral Artery Disease and other vascular
diseases. These forward-looking statements contained herein that are
not based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. Our actual results, events or developments
could be materially different from those expressed or implied by
these forward-looking statements. We can give no assurance that any
of the events or expectations will occur or be realized. By their
nature, forward-looking statements are subject to numerous known and
unknown risks and uncertainties including but not limited to those
associated with the success of research and development programs,
clinical trial programs including possible delays in patient
recruitment, the regulatory approval process, competition, securing
and maintaining corporate alliances, market acceptance of the
Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of
intellectual property, financing capability, the potential dilutive
effects of any financing, reliance on subcontractors and key
personnel and additional risk factors discussed in other documents we
file from time to time with securities authorities, which are
available through SEDAR at  http://www.sedar.com. Additionally, risks
and uncertainties are discussed in  detail in the July 31, 2010 MD&A.
The forward-looking statements contained  in this news release are
expressly qualified by this cautionary statement  are made as of the
date hereof. The Company disclaims any intention and has  no
obligation or responsibility, except as required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. The TSX Exchange does not
accept  responsibility for the adequacy or accuracy of this news
release.
For further information:
    Donald J. McCaffrey
    President & CEO
    Resverlogix Corp.
    Phone: +1-403-690-8887
    Email:  Don@resverlogix.com
    Media:
    Eric Goldman
    Rx Communications Group
    Phone: +917-322-2563
     egoldman@rxir.com
    US Institutional Investors
    Susan Noonan
    Managing Partner
    S.A. Noonan Communications, LLC
    Phone: +1-212-966-3650
    Email:  Susan@sanoonan.com

Contact:

CONTACT: For further information: Donald J. McCaffrey, President &
CEO,Resverlogix Corp., Phone: +1-403-690-8887, Email:
Don@resverlogix.com;Media: Eric Goldman, Rx Communications Group,
Phone: +917-322-2563,egoldman@rxir.com; US Institutional Investors:
Susan Noonan, ManagingPartner, S.A. Noonan Communications, LLC,
Phone: +1-212-966-3650, Email:Susan@sanoonan.com

Plus de actualités: Resverlogix Corp.
Plus de actualités: Resverlogix Corp.
  • 30.09.2010 – 15:31

    Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors

    Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that Mr. Kenneth Zuerblis has been appointed to the Company's Board of Directors. Recently Mr. Zuerblis served as the Chief Financial Officer and Senior Vice President of ImClone Systems Inc., prior to its acquisition by Eli Lilly. "I was initially attracted to Resverlogix because of RVX-208, its novel atherosclerosis ...

  • 22.06.2010 – 17:30

    Resverlogix Scientific Data Presented at EAS Congress

    Hamburg and Calgary, Canada, June 22, 2010 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference being held in Hamburg, Germany. The presentation titled "RVX-208 given orally raises ...

  • 01.02.2010 – 16:21

    Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors

    Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announced today that the Board of Directors has elected Arthur J. Higgins, CEO of Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee, to the Board effective February 1, 2010. Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer HealthCare ...